Aktis Oncology Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
(NASDAQ:AKTS), BOSTON, Jan. 13, 2026 (GLOBE NEWSWIRE) — Aktis Oncology, Inc. (“Aktis”), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies, today announced the closing of its upsized initial public offering of 17,650,000 shares of its common stock, at […]